Live Breaking News & Updates on Roberto Pellicciari

Stay updated with breaking news from Roberto pellicciari. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout

Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology. ....

New Jersey , United States , New York , Francesco Balestrieri , Roberto Pellicciari , University Of Perugia , Intercept Pharmaceuticals , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Ealth And Wellness ,

B.Riley Financial Remains a Buy on Intercept Pharma (ICPT)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Intercept Pharma (ICPT – Research Report), wi. ....

New York , United States , Piper Sandler , Marke Pruzanski , Mayank Mamtani , Intercept Pharmaceuticals Inc , Intercept Pharma , Research Report , Moderate Buy , Roberto Pellicciari ,

RBC Capital Reaffirms Their Hold Rating on Intercept Pharma (ICPT)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Intercept Pharma (ICPT – Research Report) on January 13 and set a price tar. ....

New York , United States , Marke Pruzanski , Brian Abrahams , Intercept Pharmaceuticals Inc , Research Report On , Intercept Pharma , Research Report , Moderate Buy , Roberto Pellicciari ,